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A nonimmunocompromised patient developed life-threatening 
soft tissue infection with Trichosporon asahii, Fusarium, and 
Saksenaea that progressed despite maximum antifungal ther-
apies and aggressive debridement. Interleukin-7 immuno-
therapy resulted in clinical improvement, fungal clearance, 
reversal of lymphopenia, and improved T-cell function. 
Immunoadjuvant therapies to boost host immunity may be effi-
cacious in life-threatening fungal infections.
Keywords.  fungal infection; immunotherapy; inter-
leukin-7; Trichosporon; wound infection.
Invasive fungal infections are a growing complication fol-
lowing major traumatic injuries that result in extensive soft 
tissue damage [1, 2]. The Department of Defense has identified 
combat wound infections due to invasive fungi as an emerging 
threat and a high priority [1, 2]. Despite aggressive surgical de-
bridement and antimicrobial therapy that is active against the 
particular fungal pathogens, many infections progress, with re-
sultant substantial morbidity and/or mortality. Progression of 
infection despite optimal therapy is consistent with the hypoth-
esis that impaired host immunity may be an important path-
ophysiologic mechanism that renders the fungus refractory to 
therapy [3, 4].
Drugs that boost the host immune system are increas-
ingly being tested in various infectious disorders in both im-
munosuppressed and immunocompetent patients. These 
immune-adjuvant therapies include interferon (IFN)-γ, check-
point inhibitors (anti–programmed cell death 1 (anti-PD-1), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), 
and interleukin (IL)-7 [5–8]. In some cases, these immune-
adjuvant therapies have restored indices of immune function 
and lead to control of refractory infections [5–8]. Herein, we 
describe the use of IL-7 in a patient with life-threatening soft 
tissue necrotizing fungal infection that was refractory to the 
maximal available therapy.
PATIENT CASE
A previously healthy 21-year-old man presented to the hospital 
after suffering a high-velocity motorcycle accident. He suffered 
severe injuries including comminuted pelvic fractures, multiple 
extremity factures, and a catastrophic degloving injury of the 
buttocks and perineum with gross wound soilage. He also suf-
fered vascular injuries that required angioembolization of his 
bilateral iliac arteries for hemorrhage control. On postinjury day 
7, he was noted to have a rapidly progressing necrotizing soft 
tissue infection of his buttocks and perineum. Tissue cultures 
at that time demonstrated a polymicrobial infection including 
abundant Acinetobacter spp., abundant Pseudomonas spp. (not 
Pseudomonas aeruginosa), and moderate Stenotrophomonas 
maltophila. His wound cultures also grew Trichosporon asahii, 
Saksenaea spp., and Fusarium spp. The Saksenaea isolate 
was initially identified using conventional fungal identifica-
tion methods and the sporulation inducement method for 
Saksenaea as described by Padhye and Ajello [9]. The isolate 
was then referred to Mayo Clinic (Rochester, MN, USA) for 
a species-level identification, but only a genus level could be 
determined. The Saksenaea isolate underwent susceptibility 
testing at the University of Texas Health San Antonio using the 
Clinical and Laboratory Standards Institute (CLSI) broth dilu-
tion antifungal reference method. Drug sensitivities were as fol-
lows: amphotericin B <0.03 mcg/mL, posaconazole 0.25 mcg/
mL, isavuconazole 1 mcg/mL. The Fusarium was identified by 
phenotype and microscopy. Trichosporon asahii was identified 
by matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS). No sensitivities were 
performed on Fusarium or Trichosporon asahii.
He was aggressively treated with daily or alternating-day 
operative debridement, broad-spectrum parenteral and top-
ical antibacterial and antifungal therapy. Antimicrobial 
therapy included ceftazidime, metronidazole, trimethoprim-
sulfamethoxazole, micafungin, amphotericin B, and 
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posaconazole (Figure 2), as well as VERAFLO vac instil-
lation of antimicrobials into the wound bed. The patient’s 
polymicrobial soft tissue infection continued to advance and 
was accompanied by multisystem organ failure and shock. 
Over a 4-week period, he required debridement of >3000 cm2 
of skin, subcutaneous tissue, and muscle involving the en-
tire perineum, bilateral thighs, buttocks, and circumferential 
abdominal wall (Figure 1B). Although bacterial pathogens 
were rapidly eradicated from the patient’s wound, cultures 
were persistently positive for both Trichosporon asahii and 
Saksenaea species despite triple antifungal therapy con-
sisting of posaconazole, amphotericin B, and micafungin. 
Histopathological exam of wound biopsies showed invasive 
fungal elements (Figure 1E).
Despite aggressive antimicrobial and surgical manage-
ment over the course of 7 weeks after the identification of the 
polymicrobial infection, his condition continued to worsen. 
The patient initially had an increased lymphocyte count of up 
to 2×103/µL, but soon developed persistent lymphopenia with 
neutrophilia as high as 50×103/µL. Therefore, immune-adjuvant 
therapy with recombinant human IL-7 was considered. IL-7 
induces proliferation, maturation, and activation of CD4 and 
CD8 T cells, which are severely depleted and poorly functional 
in patients with life-threatening infections including those due 
to fungal pathogens [6, 7].
Informed consent was obtained from the patient and family, 
and a test dose of IL-7 (3 µg/kg ideal body weight, intramus-
cularly; kindly provided by Dr. Michel Morre, RevImmune) 
was administered on day 59 postinjury, which was well toler-
ated (Figure 1A). Twenty-four hours later, the dosage was in-
creased to 10 µg/kg and continued every 3–4 days for 7 doses. 
The patient’s clinical status showed significant improvement 
beginning at 4–7 days after initiation of IL-7. As illustrated by 
serial pictures of the wound, the most notable change following 
initiation of IL-7 was to slow the progression of the invasive soft 
tissue necrosis (Figure 1B, green arrows).
In addition to decreased infectious spread and fungal 
proliferation, with improved wound healing and healthier-
appearing tissue margins, clinical indicators of severity of dis-
ease improved within days of IL-7 treatment initiation with 
improvement of the fever curve, tachycardia, and tachypnea 
(Supplementary Figure 1). Laboratory evidence of resolution 
of the fungal invasion included progressive decreases in total 
white blood cell count and increasing absolute lymphocyte 
counts (Figure 1A). The patient’s absolute lymphocyte count 
increased >6-fold from a low of 600 lymphocytes/µL to >4000 
lymphocytes/µL (upper limit of normal for absolute lympho-
cyte counts is 3500). Of note, the increase in the patient’s abso-
lute lymphocyte count was likely due to both the effect of IL-7 
in inducing lymphocyte proliferation and to the resolution of 
the fungal infection.
The patient had demonstrated persistent fungal growth 
with rapidly extending tissue borders requiring surgical de-
bridement over the course of 52 days before initiation of IL-7 
(Supplementary Table 1). After initiation of IL-7 therapy, an 
increasing number of tissue cultures did not identify fungal 
elements, and by the fifth dose of IL-7, the patient had persist-
ently negative cultures. Tissue histology also became negative 
for fungus at approximately the same time as tissue cultures 
(Figure 1E).
After completing IL-7 therapy, the wound beds qualita-
tively improved with development of healthy granulation tissue 
facilitating skin grafting. The patient’s blood, wound, and bone 
cultures were negative for bacterial or fungal pathogens for 
40 days after completing IL-7 therapy (see Supplementary Table 
1 for complete list of cultures). The resolution in wound fungal 
infection facilitated definitive closure of >90% (>700  cm2) 
of open wounds. Currently, the patient has a small region of 
exposed pelvic bone and a persistent perineal wound that re-
mains open due to disruption of his urethra and ongoing urine 
drainage that is pending reconstruction. A recent biopsy of the 
exposed pelvic bone and the open wound margin were positive 
for Trichosporon asahii. This is being treated with an extended 
course of isavuconazonium. There has been no recurrence of 
the life-threatening necrotizing fasciitis that resolved with IL-7 
therapy.
The effect of IL-7 in terms of improving the patient’s 
T-cell function was evaluated by an ex vivo stimulation assay 
using anti-CD3 and anti-CD28 antibodies (BioLegend, San 
Diego, CA, USA) on an IFN-γ ELISPOT assay (Cellular 
Technologies Limited, Shaker Heights, OH, USA), which 
was performed as previously described [10, 11]. The total 
number of activated, IFN-γ-producing T cells progressively 
increased from baseline (before IL-7 therapy), accompanied 
by a 1.4-fold increase in the proportion of activated T cells 
(Figure 1D).
A beneficial effect of IL-7 in infectious disorders is to increase 
expression of lymphocyte adhesion molecules and induce lym-
phocyte trafficking to sites of infection [6]. Consequently, 
immunohistochemical staining using the lymphocyte marker 
anti-CD3 was performed and demonstrated a marked increase 
in the number of lymphocytes in the biopsies from the infected 
wound (Figure 1F, right-hand panel).
To measure the specific molecular effects underlying the 
increased T-cell responsiveness induced by IL-7, we meas-
ured intracellular levels of phospho-STAT5 (pSTAT5) in CD4 
and CD8 T cells using mass cytometry. STAT5 is the primary 
T-cell differentiation signal downstream of the IL-7 receptor 
[12]. T cells were identified based on surface marker staining 
(CD45+/CD15-/CD66b-/CD56-/CD3+). We then meas-
ured the pSTAT5 signal intensity. IL-7 was associated with a 
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Figure 1. Serial clinical, anatomic, immunologic, and pathologic changes in an IL-7-treated patient with invasive fungal infection. A, Changes in WBC and ALC during the 
patient’s hospital course. Days of hospitalization are indicated on the x-axis; IL-7 was initiated on day 59. Red arrows identify administration of IL-7. B, Color photographs of 
lower back and gluteal region demonstrating necrotic and infected areas; there was serial progression of the infection with necrotic regions, which resolved following initi-
ation of IL-7. The green arrows in the second photo from the left show necrotic and poorly perfused margins. C, IL-7 mediates its effects to increase T-cell IFN-γ production 
via STAT5 signaling. CyTOF demonstrated that there was a doubling of STAT5 expression in lymphocytes obtained after initiation of IL-7 compared with pretreatment; CyTOF 
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increase in CD8-T cells (Figure 1C). These data provide a pu-
tative molecular mechanism for the increase in T-cell function 
induced by IL-7.
Patient Consent 
Informed consent was obtained from the patient and the 
patient’s parents for therapy using IL-7 and for publication of 
this case report including images of the patient’s wounds.
DISCUSSION
Critically ill patients with protracted sepsis typically de-
velop profound and persistent immunosuppression [13]. 
Numerous pathophysiologic mechanisms drive the immune 
suppression including apoptosis-induced lymphocyte deple-
tion, increased myeloid-derived suppressor cells, and T-cell 
exhaustion. Based upon a growing number of case reports, 
there is increasing recognition that therapies that boost pa-
tient immunity may be beneficial in patients with intractable 
infections that are nonresponsive to conventional therapies 
[5, 8, 13]. Particularly relevant to the present case is the use 
of the immune-adjuvants nivolumab (anti-PD-1) and IFN-γ 
in a Belgian bomb blast victim who was dying of refractory 
mucormycosis [5]. Immune-adjuvant therapy resulted in 
rapid clinical improvement, enhanced immune phenotypic 
markers, and fungal elimination.
Although a number of immuno-adjuvants are likely to be 
beneficial, IL-7 is particularly attractive because of its effects 
on a broad array of immune effector cells including CD4 and 
CD8 T cells, mucosally associated invariant T cells, and innate 
lymphoid cells that play key roles in pathogen elimination [8, 
13]. Although not presently approved for clinical use, IL-7 is 
under investigation in multiple clinical trials in infectious and 
oncologic disorders [6–8]. IL-7 has an excellent safety profile 
and has been used in >450 patients with both severe infections 
and various cancers. A double-blind, randomized, phase 2 trial 
of IL-7 in patients with sepsis showed that IL-7 was well tol-
erated, reversed sepsis-induced lymphopenia, and enhanced 
T-cell activation [6]. IL-7 has also been shown to prevent lym-
phocyte apoptosis, improve immune function, and increase 
survival in a 2-hit animal model of fungal sepsis. IL-7’s pri-
mary effect is on lymphocytes, but it will have indirect effects 
to enhance macrophage and neutrophil antimicrobial proper-
ties as well. IL-7 increases T-cell production of IFN-γ, a po-
tent activator of macrophages. IL-7 also increases T-cell IL-17 
production, which plays a critical role in fungal infections by 
enhancing neutrophil migration to sites of infection [6]. IL-7 
should be particularly advantageous in patients with profound 
and persistent lymphopenia because of its potential to prevent 
lymphocyte apoptosis and induce lymphocyte proliferation.
Although the patient in this report had no history of recur-
rent fungal infections to suggest an underlying immune de-
ficiency, persistent or recurrent mucocutaneous or invasive 
fungal infections developing in a “normal” host may be indica-
tive of genetic defects in innate or adaptive immunity [14, 15]. 
Recently, defects in the caspase recruitment domain containing 
protein 9 (CARD9) have been reported to occur in patients with 
severe fungal infections [15].
Recently, immuno-adjuvant therapy to boost host immu-
nity has been proposed as a potential additional powerful 
weapon in the armamentarium in infectious diseases [8]. The 
authors believe that the rather remarkable turnaround in the 
patient’s hospital course in the current report provides fur-
ther support for the concept of augmenting the integrity of 
the host immune system in life-threatening infections. The 
ability to evaluate the functional status of the patient’s im-
mune system, such as the use of the ELISpot assay in the 
present case (Figure 1D), will greatly advance this field by 
identifying patients who are immunosuppressed and enabling 
investigators to follow patient response to immuno-adjuvant 
therapies. Patients with intractable hospital-acquired in-
fections involving multidrug-resistant bacteria or patients 
with invasive fungal infections are likely good candidates 
for immuno-adjuvant therapies because they are almost in-
variably immunosuppressed and have high mortality. Use 
of IL-7, checkpoint inhibitors, or other immune-adjuvant 
therapies might be considered on a compassionate basis in 
patients dying of these intractable fungal infections. If im-
munotherapy does prove to be an effective new approach in 
infectious diseases, it could usher in a novel path forward in 
the battle against increasingly deadly foes.
the geometric mean of the raw values for the gated populations (not normalized), as reported by the cytometer. D, Decreased T-cell IFN-γ production is a hallmark of T-cell 
exhaustion; ELISpot analysis on PBMCs were performed serially; the far-left ELISpot well had 47 IFN-γ-producing lymphocytes (depicted as SFU) per 1000 lymphocytes plated; 
the middle and far-right wells show a progressive increase in the both the number of lymphocytes in the PBMC fraction as well as an increase in the proportion of active IFN-
γ-producing lymphocytes following CD3/CD28 stimulation. E, Immunohistochemical staining of wound margins: left panel: Gomori’s methanamine silver stain highlighting 
invasive fungal hyphae (arrows), 400×; middle panel: hematoxylin and eosin stain showing necroinflammatory debris and refractile-appearing fungal hyphae (arrows), 400×; 
right panel: Gomori’s methanamine silver stain highlighting shows clearance of invasive fungal microorganisms following IL-7 treatment; soft tissue necrosis is present, 400×. 
F, Immunohistochemical staining for CD3+ T cells. Note the marked increase in the number of lymphocytes in the wound margins that occurred after initiation of IL-7, 100×. 
Abbreviations: ALC, absolute lymphocyte count; CyTOF, time of flight mass cytometry; IFN-γ, interferon-γ; IL-7, interleukin-7; PBMCs, peripheral blood mononuclear cells; 
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Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases on-
line. Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyrighted and are the sole responsibility of the authors, so 
questions or comments should be addressed to the corresponding author.
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Figure 2. Time course of antimicrobial and surgical therapy. Graphical depiction of a timeline from the date of admission through the fourth month of his hospital course. 
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